Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Phase 2 Completed 113 enrolled Alliance for Clinical Trials in Oncology National Cancer Institute (NCI) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.

Timeline

Start: 2012-09
Primary completion: 2021-01-14
Completion: 2022-02-24

Outcome

Met primary endpoint

paper The estimated 2-year PFS was higher in the myeloablative vs nonmyeloablative arm (73% vs 51%; P = .02). PMID 38598710 ↗

Publications

Batchelor TT, Giri S, Ruppert AS, Geyer SM, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston N, Nayak L, Leonard JP, Rubenstein JL. Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Adv. 2024 Jun 25;8(12):3189-3199. doi: 10.1182/bloodadvances.2023011657.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cytarabine	Small molecule	—	Intravenous
Subject	Etoposide	Small molecule	—	Intravenous
Subject	Thiotepa	Other / unclassified	—	Intravenous
Subject	carmustine	Small molecule	—	Intravenous
Background	G-CSF	Unknown	—	—